Cellceutix Concludes Last Patient Visit in Phase 2 FDA

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed Prurisol in Patients With Mild-to-Moderate Chronic Plaque Psoriasis

BEVERLY, MA --(Marketwired - March 17, 2016) - Cellceutix ( OTC : CTIX ) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to announce the conclusion of the last patient visit in its randomized, double-blind Phase 2 trial of orally-administered Prurisol for the treatment of mild to moderate chronic plaque psoriasis. The unblinding of the study and top-line data is expected to be available in May. Although the data is still blinded, there were no safety items of concern.

"We eagerly await the Phase 2 results for Prurisol, now less than two months away," remarked Leo Ehrlich, Chief Executive Officer at Cellceutix. "We do significant laboratory research before engaging in a trial. That may be a reason why we have successfully completed three different studies on three very different compounds. The need for newer, non-biologic drugs, especially those that are easily-administered and well-tolerated for hard-to-treat psoriasis, is considerable. AbbVie's recent $595 million deal with Boehringer demonstrates the level of interest among large pharmaceutical companies in novel psoriasis treatments. Outside of Celgene's blockbuster Apremilast (Otezla), a drug expected to generate over $1 billion annually, only a handful of orally-administered drugs currently are in the pipeline for psoriasis. Prurisol is now one step closer to the goal line. We look forward to sharing the Prurisol trial results once they become known to us."

More information about the Phase 2 Trial of Prurisol for Chronic Psoriasis:

https://clinicaltrials.gov/ct2/show?term=prurisol&rank=2

More information about Prurisol:

Prurisol is a small molecule that acts through immune modulation and PRINS reduction and currently is being evaluated in a Phase 2 FDA trial under the U.S. Food and Drug Administration's 505(b)(2) pathway, which can help expedite a drug's approval by relying, in part, on clinical data from an already approved drug. In laboratory studies, Prurisol was found to be effective against psoriasis in animal models, both in induced psoriasis as well as in a xenograft model using human psoriatic tissue. Prurisol eliminated virtually all signs of psoriasis with no reoccurrence of the lesions. Prurisol is synthesized through a five-step process using commercially available starting materials.

http://cellceutix.com/prurisol/

Alerts:

Sign-up for Cellceutix email alerts is available at  http://cellceutix.com/email-alerts/

About Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Cellceutix is now preparing its FDA application for a Phase 2 ovarian cancer study. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is in a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is in a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com .

Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT: Cellceutix Corporation Leo Ehrlich Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 18

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 15

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 88

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 0

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 16

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
GE Aerospace Backs Service Members With $100K Gift

Updated Category News Views 0

A six-figure commitment can look tiny beside jet-engine budgets, yet it can matter a great deal when it reaches people navigating the awkward jump from military service into civilian life. GE Aerospace has committed $100,000 to Embry-Riddle Aeronautical University to support transitioning service members. That is the whole heart of this announcement, and frankly, it is...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
Ivanti's AI Push Rests on Data, Control and Results

Updated Category News Views 107

Enterprise AI has a nasty habit of sounding brilliant right up until it meets a messy fleet of laptops, phones, patches and permissions. Ivanti’s latest product push is aimed squarely at that unglamorous collision point: giving AI systems governed access to the operational data inside Ivanti Neurons, then keeping humans and pre-set permissions in charge of what happens...

Continue Reading
Rokt's 164% Growth Shows Checkout Ads Have Real Muscle

Updated Category News Views 0

Checkout screens have become valuable real estate, and Rokt is planting a flag right in the middle of them. The New York ecommerce technology company landed on Deloitte's 2026 Technology Fast 500 after posting 164% revenue growth from 2022 through 2025. That is a meaningful number, not decorative corporate confetti, especially in a digital-ad market where plenty of...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading

Top 5 Most Recently Viewed Articles

MindClay Launches Immersive Wellness Experience at Conference

Updated Category News Views 299

MindClay Introduces Unique Wellness Lounge MindClay Offering Attendees a First-of-its-Kind Immersive Wellness Space MindClay is set to host its innovative Interactive Museum Wellness Lounge at the upcoming Behavioral Health Tech Conference, a leading event for professionals in the field. This unique wellness space promises to immerse attendees in a revolutionary approach...

Continue Reading
Northern 3 VCT PLC Announces Share Repurchase Program Details

Updated Category News Views 148

Northern 3 VCT PLC's Recent Share Buyback Northern 3 VCT PLC is excited to share its recent activity regarding share repurchase. On July 2, 2025, the Company executed a buyback of 2,176,639 ordinary shares priced at 85.50p each, totaling approximately 1.44% of the overall issued share capital. Details of the Transaction This strategic move was made under the authority...

Continue Reading
Key Industry Leaders Unite on GS1 US Board to Innovate Supply Chains

Updated Category News Views 436

Major Appointments to the GS1 US Board of Governors In a significant development for the supply chain industry, four prominent leaders have been elected to the GS1 US Board of Governors. This newly formed board includes key executives from major companies like Kroger, Publix, Sysco, and Walmart, who will work together to enhance efficiency and transparency across various...

Continue Reading
FedTech Expands Footprint with New Boston Hub for Innovation

Updated Category News Views 334

FedTech's Strategic Expansion with New Boston Hub FedTech, a renowned venture accelerator focused on deep tech commercialization, is thrilled to announce the launch of its Boston office. This development signifies a bold move in FedTech's growth strategy and its dedication to nurturing innovation across the New England region. The office, located at 50 Milk Street, will...

Continue Reading
Revolutionizing Finance: Oracle AI Agents Enhance Efficiency

Updated Category News Views 227

Enhancing Finance with Oracle AI Agents New AI agents embedded in Oracle Fusion Cloud Applications assist finance professionals in boosting productivity, minimizing costs, and enhancing control measures. During the recent Oracle AI World event, Oracle revealed an innovative suite of AI agents designed to revolutionize traditional finance functions. By leveraging the...

Continue Reading